Eris Lifesciences to hold a board meeting on Nov 24, 2025 to consider a preferential equity issue to fund the acquisition of the remaining 30% stake in Swiss Parenterals Limited, subject to approvals.
AI Assistant
ERIS Lifesciences Ltd
2025
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.